Steven Tong
@steventong.bsky.social
Infectious diseases, clinical trials, staphylococcus and streptococcus. Reader and runner. Go Hawks!
Great to see this paper and editorial! Convincing for HIV and C neoformans.
Where is the field regarding non HIV patients? And also C gattii meningitis? Are there trials being conducted in these populations?
Where is the field regarding non HIV patients? And also C gattii meningitis? Are there trials being conducted in these populations?
January 22, 2026 at 7:35 AM
Great to see this paper and editorial! Convincing for HIV and C neoformans.
Where is the field regarding non HIV patients? And also C gattii meningitis? Are there trials being conducted in these populations?
Where is the field regarding non HIV patients? And also C gattii meningitis? Are there trials being conducted in these populations?
We're going to randomise patients in SNAP to: 1) clopidogrel vs no clopidogrel (CLOPIDO SNAP #1) and; 2) aspirin vs clopidogrel for those already on aspirin (CLOPIDO SNAP #2).
January 20, 2026 at 4:38 AM
We're going to randomise patients in SNAP to: 1) clopidogrel vs no clopidogrel (CLOPIDO SNAP #1) and; 2) aspirin vs clopidogrel for those already on aspirin (CLOPIDO SNAP #2).
Agree. It's a short, well researched, and strangely moving book. Well worth reading.
January 18, 2026 at 6:45 PM
Agree. It's a short, well researched, and strangely moving book. Well worth reading.
We are genotyping and phenotyping as many of the isolates as we can get hold of (will be most). So the analysis of blaZ and cefazolin inoculum effect will follow once done. Can't wait to see what this shows!
Altogether there were 1341 participants in SNAP, so much larger than CloCeBa.
Altogether there were 1341 participants in SNAP, so much larger than CloCeBa.
January 18, 2026 at 4:45 AM
We are genotyping and phenotyping as many of the isolates as we can get hold of (will be most). So the analysis of blaZ and cefazolin inoculum effect will follow once done. Can't wait to see what this shows!
Altogether there were 1341 participants in SNAP, so much larger than CloCeBa.
Altogether there were 1341 participants in SNAP, so much larger than CloCeBa.
Saw the post on X also - but I've decided today to deactivate my X account!
Agree with others that the numbers are too small in CloCeBa to draw strong conclusions.
Across the board in SNAP, cefazolin was better (15% mortality vs 17%). Similar in the 100 odd patients with endocarditis.
Agree with others that the numbers are too small in CloCeBa to draw strong conclusions.
Across the board in SNAP, cefazolin was better (15% mortality vs 17%). Similar in the 100 odd patients with endocarditis.
January 18, 2026 at 4:45 AM
Saw the post on X also - but I've decided today to deactivate my X account!
Agree with others that the numbers are too small in CloCeBa to draw strong conclusions.
Across the board in SNAP, cefazolin was better (15% mortality vs 17%). Similar in the 100 odd patients with endocarditis.
Agree with others that the numbers are too small in CloCeBa to draw strong conclusions.
Across the board in SNAP, cefazolin was better (15% mortality vs 17%). Similar in the 100 odd patients with endocarditis.
That's a pretty cool idea!
Laurens Manning has done some of the research with antibodies. Suggests that SDSE is the predominant cause of lower limb cellulitis!
academic.oup.com/ofid/article...
Laurens Manning has done some of the research with antibodies. Suggests that SDSE is the predominant cause of lower limb cellulitis!
academic.oup.com/ofid/article...
Serological Responses to Streptococcus pyogenes Vaccine Candidate Antigens Suggests That Streptococcus dysgalactiae Is the Predominant Cause of Lower Limb Cellulitis
AbstractBackground. A future Streptococcus pyogenes (Strep A) vaccine will ideally prevent a significant burden of lower limb cellulitis; however, natural
academic.oup.com
January 12, 2026 at 10:35 PM
That's a pretty cool idea!
Laurens Manning has done some of the research with antibodies. Suggests that SDSE is the predominant cause of lower limb cellulitis!
academic.oup.com/ofid/article...
Laurens Manning has done some of the research with antibodies. Suggests that SDSE is the predominant cause of lower limb cellulitis!
academic.oup.com/ofid/article...
Ouli’s a clinician who developed incredible bioinformatics and coding skills. Plus the smarts to use those skills to communicate ideas
January 12, 2026 at 8:34 PM
Ouli’s a clinician who developed incredible bioinformatics and coding skills. Plus the smarts to use those skills to communicate ideas
The other thing that hasn't been well measured is secondary GAS infections (that are not 'invasive'). Possible that some of these are prevented.
January 10, 2026 at 11:21 AM
The other thing that hasn't been well measured is secondary GAS infections (that are not 'invasive'). Possible that some of these are prevented.
We selectively do this in Australia. Always tricky with how rare the outcome is: ‘The secondary attack rate among household contacts was 0.219% (7 individuals) before and 0.047% (7 individuals) after’.
We are doing a RCT, but the primary outcome is throat recovery of GAS, not clinical infection
We are doing a RCT, but the primary outcome is throat recovery of GAS, not clinical infection
January 9, 2026 at 11:04 PM
We selectively do this in Australia. Always tricky with how rare the outcome is: ‘The secondary attack rate among household contacts was 0.219% (7 individuals) before and 0.047% (7 individuals) after’.
We are doing a RCT, but the primary outcome is throat recovery of GAS, not clinical infection
We are doing a RCT, but the primary outcome is throat recovery of GAS, not clinical infection
Intrigued. Can’t wait to listen!
January 8, 2026 at 10:12 AM
Intrigued. Can’t wait to listen!
Nice to see #MethodologyMonday again!
December 15, 2025 at 8:47 AM
Nice to see #MethodologyMonday again!
Non pay walled link: authors.elsevier.com/a/1mCdH3AjoX...
authors.elsevier.com
December 7, 2025 at 3:32 AM
Non pay walled link: authors.elsevier.com/a/1mCdH3AjoX...